If you've been paying much attention to the market at all the past couple of days then you know biotech and/or pharmaceutical stocks have been getting hit hard.
Some of the highest flyers such as PCRX, ISIS and INCY have taken it pretty good, but what about a blue chip like Pfizer?
You can see from the analysis below that Pfizer has actually fared quite well compared to those smaller cap stocks.
The company: Pfizer, Inc.
Ticker Symbol: PFE
Sector: Healthcare
Industry: Drug Manufacturers
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products.
Related: Five Star Stock Watch: Oracle
The company primarily offers biopharmaceutical products, including Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Norvasc, Sutent, and the Premarin family of products; and consumer healthcare products under the Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H, and Robitussin brands
Please take a look at the one-year chart of Pfizer below with added notations:
Whereas the stocks like the ones mentioned above are down anywhere up to 15 percent or more over the past few days, Pfizer is actually only down a couple of percentage points. So comparably, it has held up very well.
Pfizer has also formed somewhat of a downward channel that should be monitored for potential trading opportunities. A break through the resistance should mean higher prices, while a break of channel support should mean lower prices.
Related: Five Star Stock Watch: Nokia
Pfizer isn't set to release earnings again until the end of April.
No matter what your strategy, or when you decide to enter, always remember to use protective stops and you’ll be around for the next trade. Capital preservation is always key!
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.